Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma

Anne Tsao, Takashi Nakano, Anna K. Nowak, Sanjay Popat, Giorgio V. Scagliotti, John Heymach

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)


Malignant pleural mesothelioma (MPM) is a global health issue, the principal cause of which is exposure to asbestos. The prevalence is anticipated to rise over the next 2 decades, particularly in developing countries, due to the 30–50-year latency period between exposure to asbestos and carcinogenic development. Unresectable MPM has a poor prognosis and limited treatment options and, as such, there is a broad range of therapeutic targets of interest, including angiogenesis, immune checkpoints, mesothelin, as well as chemotherapeutic agents. Recently, the results of several randomized trials in the first-line setting combining antiangiogenic agents with chemotherapy have been reported. This review examines the scientific rationale for targeting angiogenesis in the treatment of unresectable MPM and analyzes recent clinical results with antiangiogenic agents in development (bevacizumab, nintedanib, and cediranib) for the management of MPM.

Original languageEnglish
Pages (from-to)145-154
Number of pages10
JournalSeminars in Oncology
Issue number2
Publication statusPublished - 1 Apr 2019


Dive into the research topics of 'Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this